Please sign in to follow a disease.
Alpha thalassemia spectrum
MONDO:0011399An inherited hemoglobinopathy characterized by impaired synthesis of alpha-globin chains leading to a variable clinical picture depending on the number of affected alleles.
Also known as: alpha thalassaemia, alpha thalassemia spectrum, alpha-thalassemia, thalassemia, alpha-, thalassemias, alpha-, A-thalassemia, alpha-thalassemia trait
28 clinical trials for this condition and its sub-types, 11 tagged with Alpha thalassemia spectrum itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Alpha thalassemia spectrum
-
Digenic alpha thalassemia spectrum 0 trials · 8 incl. sub-types
3 sub-types
- Hemoglobin H disease 5 trials
- Hb Bart's hydrops fetalis 3 trials
- HBA1; HBA2-related digenic alpha thalassemia spectrum 0 trials
-
Monogenic alpha thalassemia spectrum 0 trials
2 sub-types
-
New drug could cut transfusions for rare blood disorder
Disease control OngoingThis phase 2 trial tests luspatercept (Reblozyl) in adults and adolescents with alpha-thalassemia, a genetic blood disorder that causes anemia. The goal is to see if the drug can reduce the need for blood transfusions and raise hemoglobin levels. About 189 participants will recei…
Phase 2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New pill could boost red blood cells in thalassemia patients
Disease control OngoingThis phase 3 trial tests whether the drug mitapivat can improve anemia and reduce fatigue in people with alpha- or beta-thalassemia who do not need regular blood transfusions. About 194 participants received either mitapivat or a placebo daily for 24 weeks. The main goal is to se…
Phase 3 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New pill may cut transfusions for thalassemia patients
Disease control OngoingThis phase 3 study tests whether mitapivat, an oral medication, can safely reduce the number of blood transfusions needed by adults with transfusion-dependent alpha- or beta-thalassemia. Participants receive either mitapivat or a placebo for 48 weeks. The main goal is to see if m…
Phase 3 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Saliva test could unlock new blood disease treatments
Knowledge-focused OngoingThis study screens healthy volunteers aged 18-39 who self-report African ancestry for alpha globin deletions, which cause alpha thalassemia. Participants provide a one-time saliva sample by mail or in person. The goal is to learn how these genetic changes affect blood vessels, wh…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC